SEC Comment Letter for Unicycive Therapeutics, (UNCY) — Jun 11, 2026
Unicycive Therapeutics, Inc.
Date: June 11, 2026 · CIK: 0001766140 · Accession: 0000000000-26-005886
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-296545
Letter
Re: Unicycive Therapeutics, Inc. Registration Statement on Form S-3 Filed June 5, 2026 File No. 333-296545 Dear Shalabh Gupta: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions.
June 11, 2026
Shalabh Gupta Chief Executive Officer Unicycive Therapeutics, Inc. 1975 W. El Camino Real, Suite 204 Mountain View, CA 94040
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Greg Carney, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> June 11, 2026 Shalabh Gupta Chief Executive Officer Unicycive Therapeutics, Inc. 1975 W. El Camino Real, Suite 204 Mountain View, CA 94040 Re: Unicycive Therapeutics, Inc. Registration Statement on Form S-3 Filed June 5, 2026 File No. 333-296545 Dear Shalabh Gupta: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Greg Carney, Esq. </TEXT> </DOCUMENT>